RimabotulinumtoxinB (Myobloc)

Myobloc (rimabotulinumtoxinB) is covered for adults (≥18) for FDA‑approved cervical dystonia and two compendial off‑label uses (overactive bladder and excessive salivation only when associated with Parkinsonism); other uses and pediatric patients are excluded. Coverage requires documentation of the covered diagnosis, age ≥18, no hypersensitivity to botulinum toxin or excipients, no infection at the injection site, clinician awareness of safety warnings (non‑interchangeable potency units, risk of systemic toxin spread, albumin content), and approvals are valid for 12 months.

"Treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia (FDA-approved)."

Sign up to see full coverage criteria, indications, and limitations.